<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34116063</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1523-1747</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>141</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of investigative dermatology</Title>
          <ISOAbbreviation>J Invest Dermatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Genotype‒Structurotype‒Phenotype Correlations in Patients with Pachyonychia Congenita.</ArticleTitle>
        <Pagination>
          <StartPage>2876</StartPage>
          <EndPage>2884.e4</EndPage>
          <MedlinePgn>2876-2884.e4</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jid.2021.03.035</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0022-202X(21)01315-4</ELocationID>
        <Abstract>
          <AbstractText>Pachyonychia congenita (PC) is a genetic disorder of keratin that presents with nail dystrophy, painful palmoplantar keratoderma, and other clinical manifestations. We investigated the genotype‒structurotype‒phenotype correlations seen with mutations in keratin genes (keratin [K]6A, K6B, K6C, K16, K17) and utilized protein structure modeling of high-frequency mutations to examine the functional importance of keratin structural domains in PC pathogenesis. Participants of the International PC Research Registry underwent genetic testing and completed a standardized survey on their symptoms. Our results support previous reports associating oral leukokeratosis with K6A mutations and cutaneous cysts, follicular hyperkeratosis, and natal teeth with K17 mutations. Painful keratoderma was prominent with K6A and K16 mutations. Nail involvement was most common in patients with K6A mutation and least common in those with K6C mutation. Across keratin subtypes, patients with coil 2B mutations had the greatest impairment in ambulation, and patients with coil 1A mutations reported more emotional issues. Molecular modeling demonstrated that hotspot missense mutations in PC largely disrupted hydrophobic interactions or surface charge. The former may destabilize keratin dimers/tetramers, whereas the latter likely interferes with higher-order keratin filament formation. Understanding the pathologic alterations in keratin structure improves our knowledge of how PC genotype correlates with clinical phenotype, advancing insight into disease pathogenesis and therapeutic development.</AbstractText>
          <CopyrightInformation>Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Tiffany T</ForeName>
            <Initials>TT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eldirany</LastName>
            <ForeName>Sherif A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Yale School of Medicine, Yale University, New Haven, Connecticut, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bunick</LastName>
            <ForeName>Christopher G</ForeName>
            <Initials>CG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Yale School of Medicine, Yale University, New Haven, Connecticut, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Teng</LastName>
            <ForeName>Joyce M C</ForeName>
            <Initials>JMC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA. Electronic address: jteng3@stanford.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K08 AR070290</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R03 AR076484</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>UL1 TR001863</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Invest Dermatol</MedlineTA>
        <NlmUniqueID>0426720</NlmUniqueID>
        <ISSNLinking>0022-202X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053536">Keratin-16</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053537">Keratin-17</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053553">Keratin-6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>68238-35-7</RegistryNumber>
          <NameOfSubstance UI="D007633">Keratins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D056726" MajorTopicYN="Y">Genetic Association Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053536" MajorTopicYN="N">Keratin-16</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053537" MajorTopicYN="N">Keratin-17</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053553" MajorTopicYN="N">Keratin-6</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007633" MajorTopicYN="N">Keratins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053549" MajorTopicYN="N">Pachyonychia Congenita</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>CONFLICT OF INTEREST. The authors have no conflicts of interest to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>11</Day>
          <Hour>20</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34116063</ArticleId>
        <ArticleId IdType="mid">NIHMS1750023</ArticleId>
        <ArticleId IdType="pmc">PMC8922998</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jid.2021.03.035</ArticleId>
        <ArticleId IdType="pii">S0022-202X(21)01315-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ahn J, Jo I, Kang SM, Hong S, Kim S, Jeong S, et al.
Structural basis for lamin assembly at the molecular level. Nat Commun
2019;10(1):3757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6704074</ArticleId>
            <ArticleId IdType="pubmed">31434876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA. 2001;98:10037–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC56910</ArticleId>
            <ArticleId IdType="pubmed">11517324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bunick CG, Milstone LM. The x-ray crystal structure of the keratin 1-keraton 10 helix 2B heterodimer reveals molecular surface properties and biochemical insights into human skin disease. J Invest Dermatol. 2017;137(1):142–150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5514376</ArticleId>
            <ArticleId IdType="pubmed">27595935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chamcheu JC, Siddiqui IA, Syed DN, Adhami VM, Liovic M, Mukhtar H. Keratin Gene Mutations in Disorders of Human Skin and its Appendages. Arch Biochem Biophys. 2011;508:123–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3142884</ArticleId>
            <ArticleId IdType="pubmed">21176769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Connors JB, Rahil AK, Smith FJ, McLean WH, Milstone LM. Delayed-onset pachyonychia congenita associated with a novel mutation in the central 2B domain of keratin 16. Br J Dermatol. 2001;144:1058–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11359398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eldirany SA, Ho M, Bunick CG. The Interface between Keratin Structurotype and Human Disease. Structure. 2020;28:271–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7252399</ArticleId>
            <ArticleId IdType="pubmed">32130887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu T, Leachman SA, Wilson NJ, Smith FJ, Schwartz ME, Tang JY. Genotype-phenotype correlations among pachyonychia congenita patients with K16 mutations. J Invest Dermatol. 2011;131:1025–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3775566</ArticleId>
            <ArticleId IdType="pubmed">21160496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>González-Ramos J, Sendagorta-Cudós E, González-López G, Mayor-Ibarguren A, Feltes-Ochoa R, Herranz-Pinto P. Efficacy of botulinum toxin in pachyonychia congenita type 1: report of two new cases. Dermatol Ther. 2016;29:32–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26445325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hickerson RP, Leake D, Pho LN, Leachman SA, Kaspar RL. Rapamycin selectively inhibits expression of an inducible keratin (KRT6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. J Dermatol Sci. 2009;56:82–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19699613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerns ML, Hakim JM, Lu RG, Guo Y, Berroth A, Kaspar RL, et al.
Oxidative stress and dysfunctional NRF2 underlie pachyonychia congenita phenotypes. J Clin Invest. 2016;126(6):2356–2366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4887188</ArticleId>
            <ArticleId IdType="pubmed">27183391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerns ML, Hakim JM, Zieman A, Lu RG, Coulombe PA. Sexual Dimorphism in Response to an NRF2 Inducer in a Model for Pachyonychia Congenita. J Invest Dermatol. 2018;138(5):1094–1100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5912985</ArticleId>
            <ArticleId IdType="pubmed">29277538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leachman SA, Hickerson RP, Hull PR, Smith FJ, Milstone LM, Lane EB, et al.
Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J Dermatol Sci. 2008;51:151–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2587483</ArticleId>
            <ArticleId IdType="pubmed">18495438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, et al.
First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther. 2010;18:442–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2839285</ArticleId>
            <ArticleId IdType="pubmed">19935778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lomakin IB, Hinbest AJ, Ho M, Eldirany SA, Bunick CG. Crystal structure of keratin 1/10(C401A) 2B heterodimer demonstrates a proclivity for the C-terminus of helix 2B to form higher order molecular contacts. Yale J Biol Med. 2020;93:3–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7087056</ArticleId>
            <ArticleId IdType="pubmed">32226330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McLean WH, Smith FJ, Cassidy AJ. Insights into genotype-phenotype correlation in pachyonychia congenita from the human intermediate filament mutation database. J Investig Dermatol Symp Proc. 2005;10:31–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16250207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicolet S, Herrmann H, Aebi U, Strelkov SV. Atomic structure of vimentin coil 2. J Struct Biol. 2010;170:369–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20176112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parry DA. Hendecad repeat in segment 2A and linker L2 of intermediate filament chains implies the possibility of a right-handed coiled-coil structure. J Struct Biol. 2006;155(2):370–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16713299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al.
UCSF chimera – a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15264254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith FJ. Nail that mutation-keratin 17 defect in late-onset pachyonychia. J Invest Dermatol. 2004;122:x–xi.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15102104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith FJ, Hansen CD, Hull PR, Kaspar RL, McLean WH, O’Tool E, et al.
Pachyonychia Congenita. 2006. 
Jan
27 [Updated 2017 Nov 30]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith FJ, Liao H, Cassidy AJ, Stewart A, Hamill KJ, Wood P
et al.
The genetic basis of pachyonychia congenital. J Investig Dermatol Symp Proc. 2006;10:21–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16250206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spaunhurst KM, Hogendorf AM, Smith FJ, Lingala, Schwartz ME, Cywinska-Bernas A, Zeman KJ, Tang JY. Pachyonychia congenita patients with mutations in KRT6A have more extensive disease compared with patients who have mutations in KRT16. Br J Dermatol. 2012;166(4):875–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22098151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swartling C, Vahlquist A. Treatment of pachyonychia congenita with plantar injections of botulinum toxin. Br J Dermatol. 2006;154:763–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16536826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swartling C, Karlqvist M, Hymnelius K, Weis J, Vahlquist A. Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita. Br J Dermatol. 2010;163:1072–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20618323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szeverenyi I, Cassidy AJ, Chung CW, Lee BT, Common JE, Ogg SC, et al.
The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases. Hum Mutat. 2008;29:351–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18033728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al.
SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46:296–303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6030848</ArticleId>
            <ArticleId IdType="pubmed">29788355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinberg RL, Coulombe PA, Polydefkis M, Caterina MJ. Pain mechanisms in hereditary palmoplantar keratodermas. Br J Dermatol. 2020;182(3):543–551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30883689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson AK, Coulombe PA, Fuchs E. The roles of K5 and K14 head, tail, and R/K L L E G E domains in keratin filament assembly in vitro. J Cell Biol. 1992;119:401–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2289655</ArticleId>
            <ArticleId IdType="pubmed">1383231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson NJ, Leachman SA, Hansen CD, McMullan AC, Milstone LM, Schwartz ME, et al.
A large mutational study in pachyonychia congenita. J Invest Dermatol. 2011;131:1018–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21326300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao SX, Feng YG, Ren XR, Tan SS, Li L, Wang JM, et al.
A novel mutation in the second half of the keratin 17 1A domain in a large pedigree with delayed-onset pachyonychia congenita type 2. J Invest Dermatol. 2004;122:892–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15102078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Gartner U, Smith FJ, McLean WH. Statins downregulate KRT6a promoter activity: a possible therapeutic avenue for pachyonychia congenita.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21390048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zieman AG, Coulombe PA. Pathophysiology of pachyonychia congenita-associated palmoplantar keratoderma: new insights into skin epithelial homeostasis and avenues for treatment. Br J Dermatol. 2020;182(3):564–573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6814456</ArticleId>
            <ArticleId IdType="pubmed">31021398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zieman AG, Poll BG, Ma J, Coulombe PA. Altered keratinocyte differentiation is an early driver of keratin mutation-based palmoplantar keratoderma. Human Molecular Genetics. 2019;28(13):2255–2270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6602407</ArticleId>
            <ArticleId IdType="pubmed">31220272</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34116063</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1523-1747</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>141</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of investigative dermatology</Title>
          <ISOAbbreviation>J Invest Dermatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Genotype‒Structurotype‒Phenotype Correlations in Patients with Pachyonychia Congenita.</ArticleTitle>
        <Pagination>
          <StartPage>2876</StartPage>
          <EndPage>2884.e4</EndPage>
          <MedlinePgn>2876-2884.e4</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jid.2021.03.035</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0022-202X(21)01315-4</ELocationID>
        <Abstract>
          <AbstractText>Pachyonychia congenita (PC) is a genetic disorder of keratin that presents with nail dystrophy, painful palmoplantar keratoderma, and other clinical manifestations. We investigated the genotype‒structurotype‒phenotype correlations seen with mutations in keratin genes (keratin [K]6A, K6B, K6C, K16, K17) and utilized protein structure modeling of high-frequency mutations to examine the functional importance of keratin structural domains in PC pathogenesis. Participants of the International PC Research Registry underwent genetic testing and completed a standardized survey on their symptoms. Our results support previous reports associating oral leukokeratosis with K6A mutations and cutaneous cysts, follicular hyperkeratosis, and natal teeth with K17 mutations. Painful keratoderma was prominent with K6A and K16 mutations. Nail involvement was most common in patients with K6A mutation and least common in those with K6C mutation. Across keratin subtypes, patients with coil 2B mutations had the greatest impairment in ambulation, and patients with coil 1A mutations reported more emotional issues. Molecular modeling demonstrated that hotspot missense mutations in PC largely disrupted hydrophobic interactions or surface charge. The former may destabilize keratin dimers/tetramers, whereas the latter likely interferes with higher-order keratin filament formation. Understanding the pathologic alterations in keratin structure improves our knowledge of how PC genotype correlates with clinical phenotype, advancing insight into disease pathogenesis and therapeutic development.</AbstractText>
          <CopyrightInformation>Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Tiffany T</ForeName>
            <Initials>TT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eldirany</LastName>
            <ForeName>Sherif A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Yale School of Medicine, Yale University, New Haven, Connecticut, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bunick</LastName>
            <ForeName>Christopher G</ForeName>
            <Initials>CG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Yale School of Medicine, Yale University, New Haven, Connecticut, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Teng</LastName>
            <ForeName>Joyce M C</ForeName>
            <Initials>JMC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA. Electronic address: jteng3@stanford.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K08 AR070290</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R03 AR076484</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>UL1 TR001863</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Invest Dermatol</MedlineTA>
        <NlmUniqueID>0426720</NlmUniqueID>
        <ISSNLinking>0022-202X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053536">Keratin-16</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053537">Keratin-17</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053553">Keratin-6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>68238-35-7</RegistryNumber>
          <NameOfSubstance UI="D007633">Keratins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D056726" MajorTopicYN="Y">Genetic Association Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053536" MajorTopicYN="N">Keratin-16</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053537" MajorTopicYN="N">Keratin-17</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053553" MajorTopicYN="N">Keratin-6</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007633" MajorTopicYN="N">Keratins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053549" MajorTopicYN="N">Pachyonychia Congenita</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>CONFLICT OF INTEREST. The authors have no conflicts of interest to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>11</Day>
          <Hour>20</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34116063</ArticleId>
        <ArticleId IdType="mid">NIHMS1750023</ArticleId>
        <ArticleId IdType="pmc">PMC8922998</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jid.2021.03.035</ArticleId>
        <ArticleId IdType="pii">S0022-202X(21)01315-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ahn J, Jo I, Kang SM, Hong S, Kim S, Jeong S, et al.
Structural basis for lamin assembly at the molecular level. Nat Commun
2019;10(1):3757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6704074</ArticleId>
            <ArticleId IdType="pubmed">31434876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA. 2001;98:10037–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC56910</ArticleId>
            <ArticleId IdType="pubmed">11517324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bunick CG, Milstone LM. The x-ray crystal structure of the keratin 1-keraton 10 helix 2B heterodimer reveals molecular surface properties and biochemical insights into human skin disease. J Invest Dermatol. 2017;137(1):142–150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5514376</ArticleId>
            <ArticleId IdType="pubmed">27595935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chamcheu JC, Siddiqui IA, Syed DN, Adhami VM, Liovic M, Mukhtar H. Keratin Gene Mutations in Disorders of Human Skin and its Appendages. Arch Biochem Biophys. 2011;508:123–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3142884</ArticleId>
            <ArticleId IdType="pubmed">21176769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Connors JB, Rahil AK, Smith FJ, McLean WH, Milstone LM. Delayed-onset pachyonychia congenita associated with a novel mutation in the central 2B domain of keratin 16. Br J Dermatol. 2001;144:1058–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11359398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eldirany SA, Ho M, Bunick CG. The Interface between Keratin Structurotype and Human Disease. Structure. 2020;28:271–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7252399</ArticleId>
            <ArticleId IdType="pubmed">32130887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu T, Leachman SA, Wilson NJ, Smith FJ, Schwartz ME, Tang JY. Genotype-phenotype correlations among pachyonychia congenita patients with K16 mutations. J Invest Dermatol. 2011;131:1025–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3775566</ArticleId>
            <ArticleId IdType="pubmed">21160496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>González-Ramos J, Sendagorta-Cudós E, González-López G, Mayor-Ibarguren A, Feltes-Ochoa R, Herranz-Pinto P. Efficacy of botulinum toxin in pachyonychia congenita type 1: report of two new cases. Dermatol Ther. 2016;29:32–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26445325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hickerson RP, Leake D, Pho LN, Leachman SA, Kaspar RL. Rapamycin selectively inhibits expression of an inducible keratin (KRT6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. J Dermatol Sci. 2009;56:82–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19699613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerns ML, Hakim JM, Lu RG, Guo Y, Berroth A, Kaspar RL, et al.
Oxidative stress and dysfunctional NRF2 underlie pachyonychia congenita phenotypes. J Clin Invest. 2016;126(6):2356–2366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4887188</ArticleId>
            <ArticleId IdType="pubmed">27183391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerns ML, Hakim JM, Zieman A, Lu RG, Coulombe PA. Sexual Dimorphism in Response to an NRF2 Inducer in a Model for Pachyonychia Congenita. J Invest Dermatol. 2018;138(5):1094–1100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5912985</ArticleId>
            <ArticleId IdType="pubmed">29277538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leachman SA, Hickerson RP, Hull PR, Smith FJ, Milstone LM, Lane EB, et al.
Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J Dermatol Sci. 2008;51:151–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2587483</ArticleId>
            <ArticleId IdType="pubmed">18495438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, et al.
First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther. 2010;18:442–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2839285</ArticleId>
            <ArticleId IdType="pubmed">19935778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lomakin IB, Hinbest AJ, Ho M, Eldirany SA, Bunick CG. Crystal structure of keratin 1/10(C401A) 2B heterodimer demonstrates a proclivity for the C-terminus of helix 2B to form higher order molecular contacts. Yale J Biol Med. 2020;93:3–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7087056</ArticleId>
            <ArticleId IdType="pubmed">32226330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McLean WH, Smith FJ, Cassidy AJ. Insights into genotype-phenotype correlation in pachyonychia congenita from the human intermediate filament mutation database. J Investig Dermatol Symp Proc. 2005;10:31–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16250207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicolet S, Herrmann H, Aebi U, Strelkov SV. Atomic structure of vimentin coil 2. J Struct Biol. 2010;170:369–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20176112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parry DA. Hendecad repeat in segment 2A and linker L2 of intermediate filament chains implies the possibility of a right-handed coiled-coil structure. J Struct Biol. 2006;155(2):370–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16713299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al.
UCSF chimera – a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15264254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith FJ. Nail that mutation-keratin 17 defect in late-onset pachyonychia. J Invest Dermatol. 2004;122:x–xi.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15102104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith FJ, Hansen CD, Hull PR, Kaspar RL, McLean WH, O’Tool E, et al.
Pachyonychia Congenita. 2006. 
Jan
27 [Updated 2017 Nov 30]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith FJ, Liao H, Cassidy AJ, Stewart A, Hamill KJ, Wood P
et al.
The genetic basis of pachyonychia congenital. J Investig Dermatol Symp Proc. 2006;10:21–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16250206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spaunhurst KM, Hogendorf AM, Smith FJ, Lingala, Schwartz ME, Cywinska-Bernas A, Zeman KJ, Tang JY. Pachyonychia congenita patients with mutations in KRT6A have more extensive disease compared with patients who have mutations in KRT16. Br J Dermatol. 2012;166(4):875–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22098151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swartling C, Vahlquist A. Treatment of pachyonychia congenita with plantar injections of botulinum toxin. Br J Dermatol. 2006;154:763–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16536826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swartling C, Karlqvist M, Hymnelius K, Weis J, Vahlquist A. Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita. Br J Dermatol. 2010;163:1072–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20618323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szeverenyi I, Cassidy AJ, Chung CW, Lee BT, Common JE, Ogg SC, et al.
The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases. Hum Mutat. 2008;29:351–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18033728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al.
SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46:296–303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6030848</ArticleId>
            <ArticleId IdType="pubmed">29788355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinberg RL, Coulombe PA, Polydefkis M, Caterina MJ. Pain mechanisms in hereditary palmoplantar keratodermas. Br J Dermatol. 2020;182(3):543–551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30883689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson AK, Coulombe PA, Fuchs E. The roles of K5 and K14 head, tail, and R/K L L E G E domains in keratin filament assembly in vitro. J Cell Biol. 1992;119:401–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2289655</ArticleId>
            <ArticleId IdType="pubmed">1383231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson NJ, Leachman SA, Hansen CD, McMullan AC, Milstone LM, Schwartz ME, et al.
A large mutational study in pachyonychia congenita. J Invest Dermatol. 2011;131:1018–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21326300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao SX, Feng YG, Ren XR, Tan SS, Li L, Wang JM, et al.
A novel mutation in the second half of the keratin 17 1A domain in a large pedigree with delayed-onset pachyonychia congenita type 2. J Invest Dermatol. 2004;122:892–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15102078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Gartner U, Smith FJ, McLean WH. Statins downregulate KRT6a promoter activity: a possible therapeutic avenue for pachyonychia congenita.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21390048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zieman AG, Coulombe PA. Pathophysiology of pachyonychia congenita-associated palmoplantar keratoderma: new insights into skin epithelial homeostasis and avenues for treatment. Br J Dermatol. 2020;182(3):564–573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6814456</ArticleId>
            <ArticleId IdType="pubmed">31021398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zieman AG, Poll BG, Ma J, Coulombe PA. Altered keratinocyte differentiation is an early driver of keratin mutation-based palmoplantar keratoderma. Human Molecular Genetics. 2019;28(13):2255–2270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6602407</ArticleId>
            <ArticleId IdType="pubmed">31220272</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
